Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 192

1.

The targeting of human and mouse B lymphocytes by dasatinib.

Oksvold MP, Duyvestyn JM, Dagger SA, Taylor SJ, Forfang L, Myklebust JH, Smeland EB, Langdon WY.

Exp Hematol. 2015 Jan 29. pii: S0301-472X(15)00037-5. doi: 10.1016/j.exphem.2015.01.008. [Epub ahead of print]

PMID:
25641047
2.

Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma.

Blaker YN, Brodtkorb M, Maddison J, Hveem TS, Nesheim JA, Mohn HM, Kolstad A, Geisler CH, Liestøl K, Smeland EB, Holte H, Delabie J, Danielsen H.

Histopathology. 2014 Nov 27. doi: 10.1111/his.12624. [Epub ahead of print]

PMID:
25431344
3.

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.

Riihijärvi S, Fiskvik I, Taskinen M, Vajavaara H, Tikkala M, Yri O, Karjalainen-Lindsberg ML, Delabie J, Smeland E, Holte H, Leppä S.

Haematologica. 2015 Feb;100(2):238-45. doi: 10.3324/haematol.2014.113472. Epub 2014 Nov 7.

4.

Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.

Fiskvik I, Beiske K, Delabie J, Yri O, Spetalen S, Karjalainen-Lindsberg ML, Leppä S, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2014 Nov 19:1-8. [Epub ahead of print]

PMID:
25284491
5.

Loss of signalling via Gα13 in germinal centre B-cell-derived lymphoma.

Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, An J, Xu Y, Rosenwald A, Ott G, Gascoyne RD, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Vaidehi N, Staudt LM, Cyster JG.

Nature. 2014 Dec 11;516(7530):254-8. doi: 10.1038/nature13765. Epub 2014 Sep 28.

PMID:
25274307
6.

A gene panel, including LRP12, is frequently hypermethylated in major types of B-cell lymphoma.

Bethge N, Honne H, Andresen K, Hilden V, Trøen G, Liestøl K, Holte H, Delabie J, Lind GE, Smeland EB.

PLoS One. 2014 Sep 16;9(9):e104249. doi: 10.1371/journal.pone.0104249. eCollection 2014.

7.

Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.

Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, Vlassov AV, Smeland EB, Neurauter A, Pedersen KW.

Clin Ther. 2014 Jun 1;36(6):847-862.e1. doi: 10.1016/j.clinthera.2014.05.010.

8.

Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms.

Yang Y, Schmitz R, Mitala J, Whiting A, Xiao W, Ceribelli M, Wright GW, Zhao H, Yang Y, Xu W, Rosenwald A, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Wiestner A, Kruhlak MJ, Iwai K, Bernal F, Staudt LM.

Cancer Discov. 2014 Apr;4(4):480-93. doi: 10.1158/2159-8290.CD-13-0915. Epub 2014 Feb 3.

9.

The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.

Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM, Busund LT, Donnem T.

BMC Clin Pathol. 2014 Jan 20;14(1):5. doi: 10.1186/1472-6890-14-5.

10.

High dose chemotherapy with autologous stem cell transplant for patients with transformed B-cell non-Hodgkin lymphoma in the rituximab era.

Blaker YN, Eide MB, Liestøl K, Lauritzsen GF, Kolstad A, Fosså A, Smeland EB, Holte H.

Leuk Lymphoma. 2014 Oct;55(10):2319-27. doi: 10.3109/10428194.2013.871632. Epub 2014 Mar 19.

PMID:
24432894
11.

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.

Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TC, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM.

Blood. 2014 Feb 20;123(8):1214-7. doi: 10.1182/blood-2013-11-536433. Epub 2014 Jan 7.

12.

Colorectal cancer DNA methylation marker panel validated with high performance in Non-Hodgkin lymphoma.

Bethge N, Lothe RA, Honne H, Andresen K, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE.

Epigenetics. 2014 Mar;9(3):428-36. doi: 10.4161/epi.27554. Epub 2013 Dec 20.

13.

Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma.

Brodtkorb M, Lingjærde OC, Huse K, Trøen G, Hystad M, Hilden VI, Myklebust JH, Leich E, Rosenwald A, Delabie J, Holte H, Smeland EB.

Blood. 2014 Feb 13;123(7):1051-4. doi: 10.1182/blood-2013-07-512392. Epub 2013 Dec 19.

14.

Identification of highly methylated genes across various types of B-cell non-hodgkin lymphoma.

Bethge N, Honne H, Hilden V, Trøen G, Eknæs M, Liestøl K, Holte H, Delabie J, Smeland EB, Lind GE.

PLoS One. 2013 Nov 19;8(11):e79602. doi: 10.1371/journal.pone.0079602. eCollection 2013.

15.

EZH2 mutations are frequent and represent an early event in follicular lymphoma.

Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, Ott G, Campo E, Rimsza LM, Smeland EB, Chan WC, Braziel RM, Staudt LM, Wright G, Lister TA, Elemento O, Hills R, Gribben JG, Chelala C, Matolcsy A, Kohlmann A, Haferlach T, Gascoyne RD, Fitzgibbon J.

Blood. 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.

16.

Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome.

Fiskvik I, Aamot HV, Delabie J, Smeland EB, Stokke T, Heim S, Holte H.

Eur J Haematol. 2013 Oct;91(4):332-8. doi: 10.1111/ejh.12171. Epub 2013 Aug 17.

PMID:
23859481
17.

Higher World Health Organization grades of follicular lymphoma correlate with better outcome in two Nordic Lymphoma Group trials of rituximab without chemotherapy.

Wahlin BE, Sundström C, Sander B, Christensson B, Jeppsson-Ahlberg Å, Hjalmarsson E, Holte H, Østenstad B, Brown PD, Smeland EB, Kimby E.

Leuk Lymphoma. 2014 Feb;55(2):288-95. doi: 10.3109/10428194.2013.802778. Epub 2013 Jun 14.

PMID:
23662992
18.

Prognostic impact of Skp2, ER and PGR in male and female patients with soft tissue sarcomas.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT.

BMC Clin Pathol. 2013 Mar 15;13:9. doi: 10.1186/1472-6890-13-9.

19.

Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab.

Yri OE, Ekstrøm PO, Hilden V, Gaudernack G, Liestøl K, Smeland EB, Holte H.

Leuk Lymphoma. 2013 Oct;54(10):2205-14. doi: 10.3109/10428194.2013.774392. Epub 2013 Apr 2.

PMID:
23391141
20.

Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Sorbye SW, Kilvaer TK, Valkov A, Donnem T, Smeland E, Al-Shibli K, Bremnes RM, Busund LT.

PLoS One. 2012;7(10):e47068. doi: 10.1371/journal.pone.0047068. Epub 2012 Oct 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk